Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

Record Sales of $490 Million, Up 14 Percent over Third Quarter 2007

Company Raises Full Year 2008 Sales and Earnings Guidance Introduces 2009 Adjusted Net Income Guidance, Up 27 Percent over 2008

FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2008 sales of $489.7 million, compared to sales of $428.7 million for the third quarter of 2007, and at the high end of the company's guidance of $480 - $490 million. Net income for the quarter was $112.0 million and basic income per common share was $1.64. Excluding amortization expense and certain other items, adjusted net income was $92.9 million and basic adjusted income per common share for the quarter was $1.36, compared to $1.08 for the same period in 2007, exceeding the company's guidance of $1.25 to $1.35.

Central nervous system (CNS) franchise sales were $273.7 million during the quarter, a 19 percent increase compared to the same period last year. The Pain franchise sales were $117.2 million compared to $121.8 million in the third quarter of 2007. AMRIX(R) (cyclobenzaprine hydrochloride extended- release capsules) sales increased 20 percent over the second quarter 2008. Oncology franchise sales were $52.4 million, an increase of 131 percent versus 2007. Sales of TREANDA(R) (bendamustine hydrochloride) for Injection were $24.6 million for the quarter, an increase of 71 percent over the second quarter of 2008.

"More and more patients are benefiting from the novel therapies that we offer. This has resulted in record sales, and adjusted earnings that exceeded the high end of our guidance. These solid results, and our confidence in our current product portfolio, enabled us to raise our guidance for the remainder of this year and issue adjusted net income guidance for 2009 that exceeds today's First Call consensus," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Despite troubled economic conditions around the world, our
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... May 17, 2013 Tooth decay is an ... active signs of the disease. The World Health Organization says ... 100% of adults have cavities. What are the long-term effects ... showing a strong connection between the oral bacterial imbalance and ... disease so rampant, yet it is also 100% preventable? Answer: ...
(Date:5/16/2013)... Ill. (PRWEB) May 16, 2013 ... and portable models, from Cole-Parmer is designed to ... enhanced line includes: , The new Cole-Parmer® ... true workhorses in the lab. They ensure a ... and plasma specimen separation. Their standard four-place swinging ...
(Date:5/16/2013)... May 16, 2013 Scientists at the Center ... , and the California -based ... a novel therapy for reversing memory decline in mice ... find significant cognitive improvement in advanced stage AD mice. ... for reversing cognitive decline for advanced stage AD mice, ...
(Date:5/16/2013)... BioInformatics LLC New Market Report – The ... and Future Opportunities (13-004) , With barriers to ... cells market continues to increase. In this study, BioInformatics ... how satisfied scientists are with commercially available primary cells, ... ,  , Additionally, terminally differentiated cells can be ...
Breaking Biology Technology:Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3Cole-Parmer Offers Enhanced Selection of Centrifuges 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 2Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice 3BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 2BioInformatics LLC New Market Report – The Market for Primary Cells & Stem Cell-Derived Cells: Current and Future Opportunities (13-004) 3
... epigenetic anticancer program at Pharmion ... inhibitors - ... Significant opportunity to explore combination epigenetic therapies, BOULDER, Colo. ... and MethylGene Inc. (TSX: MYG) today announced a,research collaboration for ...
... /Xinhua-PRNewswire-FirstCall/ --,Kiwa Bio-Tech Products Group Corporation (OTC Bulletin Board: ... increased more than,35% over the first quarter of 2007 ... for the same period in the previous year. ... compared to only,$24,374 in the first half of 2006. ...
... COLUMBIA, Md., Aug. 14 Martek Biosciences,Corporation announced that ... of fiscal 2007 on September 5, 2007, at approximately ... 4:45 p.m. EDT Martek,will hold a conference call to ... with investors. The call is expected to be approximately ...
Cached Biology Technology:Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 2Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 3Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 4Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 5Pharmion and MethylGene Announce Collaboration to Develop Sirtuin Inhibitors as Anti-Cancer Agents 6Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 2Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 3Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 4Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 5Kiwa Bio-Tech Revenues for 1st Half Exceed $3.25 Million 6Martek to Announce Third Quarter 2007 Results on September 5, 2007 2
(Date:5/16/2013)... MIT may someday eliminate the need for patients ... blood-sugar levels and inject themselves with insulin. , ... in the body and respond by secreting the ... of pancreatic islet cells, which are destroyed in ... of system could ensure that blood-sugar levels remain ...
(Date:5/16/2013)... sports players and athletes choose to wear the color ... published in Psychological Science , a journal of ... have to do with their testosterone levels. , The ... the University of Sunderland and colleagues, demonstrated that males ... task had higher testosterone levels than other males who ...
(Date:5/16/2013)... Fish fossils that are about 23 million years ... of the gobioid order, one of the most ... Researchers led by paleontologist Professor Bettina Reichenbacher from ... Department of Earth and Environmental Sciences at Ludwig-Maximilians-Universitaet ... comprehensive analysis of fish fossils which they assign ...
Breaking Biology News(10 mins):Nanotechnology could help fight diabetes 2Nanotechnology could help fight diabetes 3High-testosterone competitors more likely to choose red 2Paleontology: The eloquence of the otoliths 2Paleontology: The eloquence of the otoliths 3
... Search & Match,the leading provider of high-performance search ... subcontractor in the U.S. Army,s Biometrics,Operations and Support ... Under the BOSS-U program twelve designated ... ceiling value of $497 million to provide,biometric services ...
... a five-year, $1.24 million grant to The University ... a research center to investigate new clean-water technologies. ... large-scale water distribution systems to sensors at individual ... contaminants. The Water and Environmental Technology, or ...
... isn,t just squeezing the middle class on land, it,s ... the Wildlife Conservation Society (WCS) and other organizations, researchers ... Eastern Africa and low fish levels. Curiously, areas ... higher fish levels. Appearing in the latest edition ...
Cached Biology News:WCC Smart Search & Match to Support U.S. Army's BOSS-U Program 2NSF to fund water and environment technology center 2Study says 'middle class' coral reef fish feel the economic squeeze 2
MOUSE ANTI HUMAN MBP (67-74) Immunogen: Human myelin basic protein...
NORMAL DONOR DONKEY SERUM...
... Probes Fc OxyBURST Green reagent (F-2902) was ... Boston University to permit measurement of the ... the subsequent oxidative burst directly in the ... consists of bovine serum albumin (BSA) that ...
Because it is manufactured at our ISO 9001–certified facilities in Eugene, Oregon, we can guarantee that FluoroPure grade propidium iodide is greater than or equal to 98% pure by HPLC....
Biology Products: